Pathophysiology of Huntington's disease: from huntingtin functions to potential treatments.
about
Multiple Aspects of Gene Dysregulation in Huntington's DiseaseTreatment of Huntington's disease.Iron dysregulation in Huntington's diseasePossible involvement of self-defense mechanisms in the preferential vulnerability of the striatum in Huntington's diseaseHigh-content chemical and RNAi screens for suppressors of neurotoxicity in a Huntington's disease modelThe search for sensitive biomarkers in presymptomatic Huntington disease.Integrating the stress response: lessons for neurodegenerative diseases from C. elegansIncreased prothrombin, apolipoprotein A-IV, and haptoglobin in the cerebrospinal fluid of patients with Huntington's diseaseMultiple phenotypes in Huntington disease mouse neural stem cells.Genetic and pharmacological inhibition of calcineurin corrects the BDNF transport defect in Huntington's disease.Tricyclic pyrone compounds prevent aggregation and reverse cellular phenotypes caused by expression of mutant huntingtin protein in striatal neurons.Dopamine D2 receptor stimulation potentiates PolyQ-Huntingtin-induced mouse striatal neuron dysfunctions via Rho/ROCK-II activationTetrabenazine as anti-chorea therapy in Huntington disease: an open-label continuation study. Huntington Study Group/TETRA-HD Investigators.Huntingtin interacts with the cue domain of gp78 and inhibits gp78 binding to ubiquitin and p97/VCP.CREB is a key regulator of striatal vulnerability in chemical and genetic models of Huntington's disease.Altered manganese homeostasis and manganese toxicity in a Huntington's disease striatal cell model are not explained by defects in the iron transport system.Development of a grape seed polyphenolic extract with anti-oligomeric activity as a novel treatment in progressive supranuclear palsy and other tauopathiesDrosophila Models of Huntington's Disease exhibit sleep abnormalitiesTetrabenazine: the first approved drug for the treatment of chorea in US patients with Huntington disease.Huntington disease (chorea) in the middle East.Mitogen- and stress-activated protein kinase 1-induced neuroprotection in Huntington's disease: role on chromatin remodeling at the PGC-1-alpha promoter.Striatal infusion of glial conditioned medium diminishes huntingtin pathology in r6/1 mice.Early atrophy of pallidum and accumbens nucleus in Huntington's disease.Neuronal store-operated calcium entry pathway as a novel therapeutic target for Huntington's disease treatment.Impaired mitochondrial energy metabolism as a novel risk factor for selective onset and progression of dementia in oldest-old subjects.Loss of the thyroid hormone-binding protein Crym renders striatal neurons more vulnerable to mutant huntingtin in Huntington's disease.Exploratory 7-Tesla magnetic resonance spectroscopy in Huntington's disease provides in vivo evidence for impaired energy metabolism.Ubiquitin: a potential cerebrospinal fluid progression marker in Huntington's disease.The mitochondrial death pathway: a promising therapeutic target in diseasesLatrepirdine, a potential novel treatment for Alzheimer's disease and Huntington's chorea.Brain metabolite alterations and cognitive dysfunction in early Huntington's disease.CYP46A1, the rate-limiting enzyme for cholesterol degradation, is neuroprotective in Huntington's disease.The endocannabinoid system as a target for the treatment of motor dysfunction.Emerging drug therapies in Huntington's disease.Bone-marrow-derived mesenchymal stem cell therapy for neurodegenerative diseases.BDNF and exercise enhance neuronal DNA repair by stimulating CREB-mediated production of apurinic/apyrimidinic endonuclease 1.Tetrabenazine.Polyphenolic compounds for treating neurodegenerative disorders involving protein misfolding.Bringing natural products into the fold - exploring the therapeutic lead potential of secondary metabolites for the treatment of protein-misfolding-related neurodegenerative diseases.Experimental surgical therapies for Huntington's disease.
P2860
Q24605880-68BE24B8-7E7D-496B-99F1-BDEC9F1BAAD1Q26782004-46A8B843-6091-4EB6-83B2-F1BE867303E3Q26829932-F1F8B2AD-C184-43B3-8BE2-F10FE405734FQ27011417-3E278F76-6843-418D-886A-9BA37D0A7607Q27323092-3BE40151-04BD-4A42-8947-951FE1F9EFE5Q27691292-08D8B585-A1CF-486B-A0BE-5E3120B50D61Q28305190-FD1D6CE3-28A9-482E-AC2E-A48289DE14DAQ28477022-81EF8248-7507-4434-8D27-7C9E5D126CE8Q30419653-DD4486F9-756F-4857-9D76-A7B2A20F71D0Q30491641-114159B0-7580-423B-8BA6-D3C7B0F65D69Q33479778-12FB879B-103B-4731-B9DD-EF9E22E12CFFQ33519066-0C7FBE00-D748-4461-A2E5-66EA48CE25E8Q33519733-35A4FCC3-BF1F-4B59-A1AA-80924E0C10E1Q33529116-5CB6C432-4796-40B4-B41F-F9F013BA80FFQ33908482-717438C3-F248-4D0B-924D-62BABF935164Q34071987-EF3AA9B3-2E61-42AB-8EB6-007CCF5C9692Q34154643-02AAEB66-B26B-4C07-8EE6-77B7C4026E75Q34165011-62080B00-BCE4-45DC-A92B-5BE5E69C94D9Q34184185-EEC49B42-D25D-4DEB-9CA6-A3880E93EE58Q34782712-0C7A06FD-3DEC-42B9-A2CD-60A1A50B6EADQ34994779-793A552D-FA8D-4E10-8230-87FF6C6E0B9DQ34998578-78FB0E22-F535-400E-BDFE-C0FC8BE8F79CQ35037327-2B2B7172-B280-4CED-8A5A-127474A83F89Q35072356-63045BC8-FC63-4553-9F05-357A29BA1BC6Q35168684-9FC3C021-EBB3-401E-BBC7-2A1195871A5BQ35239326-4471E7E3-FD0C-4E8E-A301-662FBAFB7E85Q35577423-E9655668-26F9-44FC-B01D-B8D0AFBE9179Q35663352-D2323F2D-2FCA-4A87-8590-BB5C19B7EE58Q35831981-21954AEA-C7B0-4ED4-89D8-BDC31B0885F6Q35940409-3879836E-FA7E-4F2E-917B-E25B43D5FB12Q36059092-7372220C-8DA4-4E52-A8EC-4CA7EA5AA420Q36615488-F8A40951-DCB0-4379-BA56-AB94276157C0Q37394164-7535B2BB-2EBC-4B3E-B1C0-5B0CFD23774EQ37488273-8AC6003B-3B3C-432F-831E-C9DC25B0B675Q37613043-75F8E0C7-FE84-4F9C-8076-85221BEB5DE5Q37628129-076EB55A-4A80-439E-A3BF-C2FC687F1D59Q37636156-C363CCF3-7F79-4D02-B6AA-8C748CC54105Q37775038-FE665549-E74E-41D7-BEAA-5B0AB660BCE4Q37798463-2B036099-7753-4D70-A5BC-5B9D88B50B83Q37825629-EE2B6D75-FEAC-4FF9-8F7D-3842D6E90798
P2860
Pathophysiology of Huntington's disease: from huntingtin functions to potential treatments.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on August 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Pathophysiology of Huntington' ...... tions to potential treatments.
@en
Pathophysiology of Huntington' ...... tions to potential treatments.
@nl
type
label
Pathophysiology of Huntington' ...... tions to potential treatments.
@en
Pathophysiology of Huntington' ...... tions to potential treatments.
@nl
prefLabel
Pathophysiology of Huntington' ...... tions to potential treatments.
@en
Pathophysiology of Huntington' ...... tions to potential treatments.
@nl
P2093
P1476
Pathophysiology of Huntington' ...... tions to potential treatments.
@en
P2093
Emmanuel Roze
Frédéric Saudou
Jocelyne Caboche
P304
P356
10.1097/WCO.0B013E328304B692
P577
2008-08-01T00:00:00Z